Analytical Data
-
Gene name
CDK2
- Application
-
Alternative Names
CDKN2; p33(CDK2); Cell division protein kinase 2; p33 protein kinase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P24941
-
Expression Region
Gln5~Pro294
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclin-dependent kinase 2 (CDK2) is a crucial enzyme that regulates the cell cycle and plays a vital role in cellular processes such as DNA replication and cell division. Its activity is primarily controlled by its association with cyclins and various regulatory proteins. Dysregulation of CDK2 has been implicated in numerous diseases, including cancer, where it can lead to uncontrolled cell proliferation. The study of recombinant CDK2 proteins is essential for understanding its biochemical properties, functional mechanisms, and interactions with inhibitors. Researchers have developed various recombinant forms of CDK2, facilitating studies on its catalytic activity and the effects of specific mutations. Additionally, the production of CDK2 as a recombinant protein allows for high-throughput screening of potential therapeutics aimed at modulating its activity. By investigating CDK2's structure-function relationship and its role in cancer biology, scientists aim to identify novel targets for cancer treatment and better understand the molecular pathways involved in tumorigenesis. Overall, the exploration of recombinant CDK2 offers significant insights into cell cycle regulation and potential strategies for therapeutic intervention in diseases associated with its dysregulation.
